Evotec Reports Second Quarter And First Half 2026 Results, Updates Full-Year Outlook; Stock Down
Evotec SE (EVO) reported Q2 2026 revenue of €143.5m, down from €171.2m, and adjusted EBITDA of -€20.8m. H1 revenue fell to €300.1m from €371.2m, with adjusted EBITDA -€42.7m. It reaffirmed FY2026 guidance: revenue €570-€610m and adjusted EBITDA -€70 to -€105m, citing partnership phasing and slower new ramp-ups.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of weaker Q2/H1 financials and a reduced FY2026 revenue and adjusted EBITDA outlook, with management attributing most of the revenue reduction to partnership phasing and slower ramp-up into 2027.
Market read
Guidance reduction and deeper adjusted EBITDA losses are likely to drive estimate revisions and near-term positioning, especially given the explicit shift of revenue phasing into 2027.
What to watch
Segment detail suggests the H1 decline includes a non-repeat of a prior-year Sandoz license sale, so normalized comparisons may be less bearish than headline revenue declines imply.
Background
Evotec is a drug discovery and development company reporting quarterly and half-year results, with revenue influenced by strategic partnerships and transformation initiatives.
Ticker impact
Evotec reported Q2 and H1 2026 results with revenues down year over year and widened adjusted EBITDA losses, plus a reduced full-year outlook.
Bearish bias for the next few sessions as traders reprice FY2026 revenue phasing into 2027 and the weaker partnership contribution.
The article discloses concrete quarterly and half-year financials and a revised full-year guidance range, including that ~85% of the revenue reduction is due to partnership phasing and slower ramp-up.
Market effects
Signals continued volatility in drug discovery services demand and partnership-driven revenue recognition, which can weigh on sentiment for similar CRO/drug-discovery peers.
Hamburg-listed biotech services name weakness may modestly affect German small/mid-cap healthcare sentiment.
Limited direct global read-through, but guidance cuts tied to partnership phasing can influence broader biotech services risk appetite.
Counterpoint
The guidance cut is largely attributed to revised phasing into 2027 rather than a collapse in underlying commercial momentum, which could support a rebound if investors focus on forward ramp.
Key entities
- companyEvotec SE
Subject of the article, reporting Q2 and H1 2026 results and updating full-year 2026 guidance.
- programHorizon transformation program
Cost discipline initiative referenced as lowering R&D expenses in H1 2026.
- segmentJust - Evotec Biologics (JEB)
Biologics segment whose Q2 and H1 revenue declines are partly linked to non-repeat of a prior-year license sale.
